Document:

First Supplemental Indenture

 Exhibit 4.20 
  
 EXECUTION COPY 
  
 ANTHEM, INC. 
  
 and 
  
 THE
BANK OF NEW YORK 
                                 Trustee 
  

  
 FIRST SUPPLEMENTAL INDENTURE 
  
 Dated as of August 27, 2004 
  

  
 Supplement to Senior Note Indenture Dated as of December 31, 2002

  
 3.50% Notes due 2007 
  

 FIRST SUPPLEMENTAL INDENTURE 
  
 FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”), dated as of August 27, 2004, between ANTHEM,
INC., an Indiana corporation (hereinafter called the “Company”), having its principal office at 120 Monument Circle, Indianapolis, Indiana 46204 and THE BANK OF NEW YORK, a New York banking corporation, as Trustee (hereinafter called the
“Trustee”) under the Indenture (as hereinafter defined). 
  
 RECITALS OF THE COMPANY 
  
 WHEREAS, the Company has
heretofore executed and delivered to the Trustee the Senior Note Indenture, dated as of December 31, 2002 (herein called the “Indenture”), providing for the issuance from time to time of one or more series of the Company’s unsecured
promissory notes or other evidences of indebtedness (herein and in the Indenture called the “Securities”), the forms and terms of which are to be determined as set forth in Section 2.01 of the Indenture; and 
  
 WHEREAS, Section 9.01 of the Indenture provides, among other things, that the
Company and the Trustee may enter into indentures supplemental to the Indenture for, among other things, the purpose of (a) establishing the form or terms of Securities of any series and (b) changing or adding new provisions to the Indenture in
certain circumstances; and 
  
 WHEREAS, the Company desires to
create a series of the Securities in a total aggregate principal amount of U.S. $200,000,000, which series shall be designated as the 3.50% Notes due 2007 (the “2007 Notes”), and all action on the part of the Company necessary to authorize
the issuance of the 2007 Notes under the Indenture and this First Supplemental Indenture has been duly taken; and 
  
 WHEREAS, all acts and things necessary to make the 2007 Notes, when executed by the Company and authenticated and delivered by the Trustee as provided in
the Indenture and this First Supplemental Indenture, the valid and binding obligations of the Company and to constitute these presents a valid and binding supplemental indenture and agreement according to its terms, have been done and performed;

  

 NOW, THEREFORE, THIS FIRST SUPPLEMENTAL INDENTURE WITNESSETH: 
  
 That in consideration of the premises and the issuance of the 2007 Notes, the
Company covenants and agrees with the Trustee, for the equal and proportionate benefit (subject to the provisions of the Indenture) of the respective holders from time to time of the 2007 Notes and of all other Securities, as follows: 
  
 ARTICLE ONE 
  
 CREATION OF THE NOTES 
  
 SECTION 1.1. Designation of Series. Pursuant to the terms hereof and Section 2.01 of the Indenture, the Company hereby creates a series of
Securities designated as the 3.50% Notes due 2007, which 2007 Notes shall be deemed “Securities” for all purposes under the Indenture. 
  
 SECTION 1.2. Form of Notes. The form of the 2007 Notes shall be substantially in the form set forth in Exhibit A attached hereto, which is
incorporated herein and made part hereof. The 2007 Notes shall bear interest, be payable and have such other terms as are stated in said form of 2007 Notes attached hereto as Exhibit A and in the Indenture, as supplemented by this First
Supplemental Indenture. 
  
 SECTION 1.3. Stated Maturity.
The 2007 Notes shall mature and the principal thereof shall be due and payable together with all accrued and unpaid interest thereon on September 1, 2007 (the “Stated Maturity”). 
  
 SECTION 1.4. Limit on Amount of Series. The 2007 Notes shall not
exceed U.S. $200,000,000 in aggregate principal amount Outstanding under the Indenture at any time. The 2007 Notes may, upon the execution and delivery of this First Supplemental Indenture or from time to time thereafter, be executed by the Company
and delivered to the Trustee for authentication, and the Trustee shall thereupon authenticate and deliver said 2007 Notes upon the delivery of a Company Order. 
  

SECTION 1.5. Redemption. The 2007 Notes shall not be redeemable at the option of the Company prior to their Stated Maturity. 
  
 SECTION 1.6. No Sinking Fund. No sinking fund will be provided with
respect to the 2007 Notes. 
  
 SECTION 1.7. Notes Not
Convertible or Exchangeable. The 2007 Notes will not be convertible or exchangeable for other securities or property. 
  
 SECTION 1.8. Issuance of Notes; Selection of Depository. The 2007 Notes shall be issued as Global Securities in registered form, without coupons.
The initial Depository for the 2007 Notes shall be The Depository Trust Company. 
  
 SECTION 1.9. No Additional Amounts. No additional amounts shall be payable with respect to the Notes. 
  

 - 2 - 

 ARTICLE TWO 
  
 APPOINTMENT OF THE TRUSTEE AS AGENT AND REGISTRAR; 
 PLACE OF PAYMENT 
  
 SECTION 2.1. Appointment of
Trustee as Agent. Pursuant and subject to the Indenture, the Company hereby constitutes the Trustee to act as the principal paying agent for the 2007 Notes, effective upon execution and delivery of this First Supplemental Indenture. By execution
and delivery of this First Supplemental Indenture, the Trustee hereby accepts appointment as paying agent with respect to the 2007 Notes, and agrees to serve as paying agent upon the terms and conditions set forth in the Indenture and in this First
Supplemental Indenture. Pursuant to Section 4.02 of the Indenture, the Company hereby designates the Corporate Trust Office of the Trustee as the office of the Company where the 2007 Notes may be presented for payment, where 2007 Notes may be
presented for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the 2007 Notes, the Indenture and this First Supplemental Indenture may be given or served; provided that there shall at all times
be a Place of Payment in respect of the 2007 Notes at the office or agency of the Trustee in The City of New York, New York, and the Company hereby appoints the Trustee and such office or agency for such purpose. The Company hereby appoints the
Trustee as its agent for all such purposes and the Trustee hereby accepts its appointment for such purposes. 
  
 SECTION 2.2. Appointment of Trustee as Registrar. Pursuant to Section 2.05(b) of the Indenture, the Company hereby appoints the Trustee to act as
Security Registrar for the 2007 Notes. 
  
 SECTION 2.3. Rights,
Powers, Duties and Obligations of the Trustee. Any rights, powers, privileges, immunities, duties and obligations by any provisions of the Indenture conferred or imposed upon the Trustee shall, insofar as permitted by law, be conferred or
imposed upon and exercised or performed by the Trustee with respect to the 2007 Notes. 
  
 ARTICLE THREE 
  
 DEFEASANCE

  
 SECTION 3.1. Defeasance Applicable to Notes. Pursuant
to Section 11.01 of the Indenture, the Company, will have (i) the option of legal defeasance of the 2007 Notes and (ii) the option of covenant defeasance, in each case, upon the terms and conditions contained in Article Eleven of the Indenture.

  

 - 3 - 

 ARTICLE FOUR 
  
 AMENDMENTS 
  
 SECTION 4.1. The definition of “Corporate Trust Office” contained in Section 1.01 of the Indenture is hereby amended to read in its entirety as
follows: 
  
 “Corporate Trust Office: The
term ‘Corporate Trust Office’ shall mean the office of the Trustee at which at any particular time its corporate trust business shall be principally administered, which office at the date of the execution of this Indenture is located at
101 Barclay Street, Floor 8W, New York, New York, 10286; Attention: Corporate Trust Division — Corporate Finance Unit, or such other office or address as the Trustee may designate from time to time by notice to Company.” 
  
 SECTION 4.2. Section 2.11 of the Indenture is hereby amended by adding the
following subsection: 
  
 “(d) Members of or
participants (collectively, the “Participants”) in the Depository shall have no rights under this Indenture with respect to any Global Security held on their behalf by or on behalf of the Depository, and such Depository or its nominee, as
the case may be, may be treated by the Company, the Trustee and any agent of the Company or the Trustee as the Holder of such Global Security for all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company, the
Trustee or any agent of the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by the Depository or impair, as between the Depository and Participants, the operation of customary practices
governing the exercise of the rights of a Holder of any Security, including but not limited to the granting of proxies or other authorization of Participants to give or take any request, demand, authorization, direction, notice, consent, waiver or
other action which a Holder is entitled to give or take under this Indenture.” 
  
 ARTICLE FIVE 
  
 MISCELLANEOUS

  
 SECTION 5.1. Execution as Supplemental Indenture. The
Indenture, as supplemented by this First Supplemental Indenture, is in all respects ratified and confirmed. This First Supplemental Indenture is executed and shall be construed as an indenture supplemental to the Indenture and, as provided in the
Indenture, the Indenture shall be and be deemed to be modified and amended in accordance herewith, and all of the terms and conditions of this First Supplemental Indenture shall be and be deemed to be part of the terms and conditions of the
Indenture for any and all purposes. Except as herein expressly otherwise defined, the use of the terms and expressions herein is in accordance with the definitions, uses and constructions contained in the Indenture. 
  

 - 4 - 

 SECTION 5.2. Responsibility for Recitals, Etc. The recitals herein and in the 2007 Notes (except
in the Trustee’s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representations as to the validity or sufficiency of
this First Supplemental Indenture or of the 2007 Notes. The Trustee shall not be accountable for the use or application by the Company of the 2007 Notes or of the proceeds thereof. 
  
 SECTION 5.3. Provisions Binding on Company’s Successors. All the covenants, stipulations, promises and
agreements of the Company contained in this First Supplemental Indenture shall bind the Company’s successors and assigns whether so expressed or not. 
  
 SECTION 5.4. New York Contract. This First Supplemental Indenture and each 2007 Note shall be governed by and construed in accordance with the laws
of the state of New York (including without limitation Section 5-1401 of the New York General Obligations Law or any successor to such statute). 
  
 SECTION 5.5. Execution and Counterparts. This First Supplemental Indenture may be executed with counterpart signature pages or in any number of
counterparts, each of which shall be an original but such counterparts shall together constitute but one and the same instrument. 
  
 SECTION 5.6. Defined Terms. Terms defined in the Indenture and used and not otherwise defined in this First Supplemental Indenture shall have the
respective meanings assigned to them in the Indenture. 
  

 - 5 - 

 IN WITNESS WHEREOF, the parties hereto have caused this First Supplemental Indenture to be duly executed
by their respective officers hereunto duly authorized, all as of the day and year first above written. 
  

			
	 ANTHEM, INC.

		
	By:	 	/s/    MICHAEL L. SMITH        
	 Name:
	 	Michael L. Smith
	 Title:
	 	Executive Vice President and Chief
Financial and Accounting Officer

  

			
		
	Attest:	 	/s/    MICHAEL C. WYATT        
	 Name:
	 	Michael C. Wyatt
	 Title:
	 	Executive Counsel and Asst. Secretary

  

			
	 THE BANK OF NEW YORK,
 as
Trustee

		
	By:	 	/s/    STEVEN D.
TORGESON        
	 Name:
	 	Steven D. Torgeson
	 Title:
	 	Vice President

  

 - 6 - 

 EXHIBIT A TO FIRST SUPPLEMENTAL INDENTURE 
  
 FORM OF 2007 NOTE 
  
 Unless this certificate is presented by an authorized representative of The
Depository Trust Company, a New York corporation (“DTC”), to Issuer or its agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as is
requested by an authorized representative of DTC (and any payment is made to Cede & Co. or to such other entity as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO
ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein. 
  
 THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE
THEREOF. EXCEPT AS OTHERWISE PROVIDED IN SECTION 2.11 OF THE INDENTURE, THIS SECURITY MAY BE TRANSFERRED IN WHOLE, BUT NOT IN PART, ONLY TO ANOTHER NOMINEE OF THE DEPOSITORY OR TO A SUCCESSOR DEPOSITORY OR TO A NOMINEE OF SUCH SUCCESSOR DEPOSITORY.
THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITORY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE. 
  
 ANTHEM, INC. 
  
 3.50% NOTE DUE 2007 
  

			
	No.	  	U.S. $200,000,000
	CUSIP NO. 03674B AE 4	  	 

  
 Anthem, Inc., a
corporation duly organized and existing under the laws of the State of Indiana (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay
to Cede & Co., or registered assigns, the principal sum of U.S. $200,000,000 on September 1, 2007, and to pay interest thereon from August 27, 2004, or from the most recent Interest Payment Date to which interest has been paid or duly provided
for, semi-annually on March 1 and September 1 in each year, commencing March 1, 2005, at the rate of 3.50% per annum, until the principal hereof is paid or made available for payment. The interest so payable, and punctually paid or duly provided
for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on February 15 or August 15 (whether or not a
Business Day), as the case may be, next preceding such Interest Payment Date (the “Regular Record Date”). Any such interest not so punctually paid or duly provided for (“Defaulted Interest”) will forthwith cease to be payable to
the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of 

  

 A-1 

 
business on a date to be fixed by the Trustee for the payment of such Defaulted Interest (“Special Record Date”), notice whereof shall be given to
Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series
may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. Interest payable at the Stated Maturity date (if other than an Interest Payment Date) shall be payable upon surrender of this
Security at the office of the paying agent. 
  
 Payment of the
principal of (and premium, if any) and interest on this Security will be made at the office or agency of the Company maintained for that purpose in The City of New York, New York, in such coin or currency of the United States of America as at the
time of payment is legal tender for payment of public and private debts; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the Person entitled thereto as such address shall
appear in the Security Register. 
  
 Reference is hereby made to
the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 
  
 Unless the Certificate of Authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual
signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
  
 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 
  

									
	 	 	 	 	 ANTHEM, INC.

	 Dated: ______________
	 	 	 	 
					
	 	 	 	 	 	 	By:	 	 
	 	 	 	 	 	 	 Name:
	 	 
	 	 	 	 	 	 	 Title:
	 	 

  

 A-2 

 CERTIFICATE OF AUTHENTICATION 
  
 This is one of the Securities of the series designated in accordance with, and referred to in, the within-mentioned
Indenture. 
  
 Dated:
                             
  

			
	 THE BANK OF NEW YORK,
 as
Trustee

		
	By:	 	 
	 	 	 Authorized Signatory

  

 A-3 

 [FORM OF REVERSE] 
  

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one
or more series under a Senior Note Indenture, dated as of December 31, 2002 (herein called the “Indenture,” which term shall have the meaning assigned to it in such instrument), between the Company and The Bank of New York, as Trustee
(herein called the “Trustee,” which term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder
of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof, limited in aggregate
principal amount to $200,000,000. 
  
 The Indenture contains
provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture.

  
 If an Event of Default with respect to Securities of this
series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture. 
  
 The Indenture permits, with certain exceptions as therein provided, the supplement thereof and the modification of the
rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of
the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions for the waiver of compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their
consequences only with the consent of the Holders of each Security then Outstanding and affected thereby. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this
Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security. 
  
 As provided in and subject to the provisions of the Indenture, the Holder of
this Security shall not have the right to institute any suit, action or proceeding in equity or at law upon or under or with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such
Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, and unless the Holders of not less than 25% in aggregate principal amount of the Securities of this series
at the time Outstanding shall have made written request to the Trustee to institute such action, suit or proceeding in respect of such Event of Default as Trustee and offered the Trustee such reasonable indemnity as it may require, and the Trustee
shall have failed to institute any such action, suit of proceeding for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for 

  

 A-4 

 
the enforcement and any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 
  
 No reference herein to the Indenture and no provision of this Security or of
the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency, herein
prescribed. 
  
 As provided in the Indenture and subject to
certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company designated for such purpose, duly
endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Securities
of this series and of like tenor, of authorized denominations and for a like aggregate principal amount, will be issued to the designated transferee or transferees. 
  
 The Securities of this series are issuable only in registered form without coupons in denominations of $1,000 and any
integral multiple thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a
different authorized denomination, as requested by the Holder surrendering the same. 
  
 No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.

  
 Prior to due presentment of this Security for registration of
transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the
Trustee nor any such agent shall be affected by notice to the contrary. 
  
 All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture. 
  

 A-5Amended and Restated Information and Registration Rights Agreement

 Exhibit 4.1 
  

  
 CORUS PHARMA, INC. 
  
 AMENDED AND RESTATED 
 INFORMATION AND REGISTRATION RIGHTS AGREEMENT 
  

  
 April 9, 2004 
  
 Initial Closing: April 9, 2004 
 Second Closing: April 21, 2004 
 Third Closing: May 7, 2004 
 Fourth
Closing: June 30, 2004 
  

 CORUS PHARMA, INC. 
  
 AMENDED AND RESTATED INFORMATION AND 
 REGISTRATION RIGHTS AGREEMENT 
  
 THIS AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of April 9, 2004, by and among Corus Pharma, Inc., a Delaware corporation (the “Company”),
and the undersigned holders of shares of the Company’s Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock listed on the attached Exhibit A, as it may be amended from time to time pursuant to the terms hereof
(collectively, the “Investors”). 
  
 RECITALS 
  
 A. Certain of the Investors (the
“Series A Investors”) hold shares of the Company’s Series A Preferred Stock, par value $0.001 (the “Series A Preferred Stock”) and certain of the Investors (the “Series B
Investors”) hold shares of the Company’s Series B Preferred Stock, par value $0.001 (the “Series B Preferred Stock”). The Company, the Series A Investors and the Series B Investors are parties to the Amended
and Restated Information and Registration Rights Agreement dated as of February 21, 2003 by and among the Company and such Investors (the “Prior Rights Agreement”). 
  
 B. The Company and certain Investors (the “Series C
Investors”) have entered into the Series C Stock Purchase Agreement (the “Purchase Agreement”) dated as of the date hereof, which provides for the issuance and sale by the Company and purchase by the Series C
Investors of the Company’s Series C Preferred Stock, par value $0.001 (the “Series C Preferred Stock”). 
  
 C. In connection with the purchase and sale of the Company’s Series C Preferred Stock pursuant to the Purchase Agreement, the Company and the
Investors desire to provide for certain rights of the Investors. The Series B Investors, the Series A Investors and the Company acknowledge that they are entering into this Agreement as an inducement to and in consideration of the purchase of shares
of the Company’s Series C Preferred Stock by the Series C Investors, and agree that this Agreement shall amend and restate the Prior Rights Agreement in its entirety. 
  
 THE PARTIES AGREE AS FOLLOWS: 
  
 1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
  
 1.1 “Commission” shall mean the
Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 
  
 1.2 “Convertible Securities” shall mean the Series A Preferred Stock, Series B Preferred Stock and Series C
Preferred Stock. 
  
 1.3 “Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended. 
  

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 1.4 “Form S-3” shall mean such form under the Securities Act
as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the Commission that permits inclusion or incorporation of substantial information by reference to documents filed by the Company with the
Commission. 
  
 1.5
“Holder” shall mean any holder of outstanding Registrable Securities, but only if such holder is one of the Investors or an assignee or transferee of registration rights as permitted by Section 14. 
  
 1.6 “Initiating Holders” shall mean
Holders who in the aggregate hold at least 20% of the Registrable Securities. 
  
 1.7 “Material Adverse Event” shall mean any change, event or effect that (a) is materially adverse to the general affairs, business, operations, assets, condition (financial or otherwise) or
results of operations or prospects of the Company and its subsidiaries taken as a whole, or (b) is reasonably foreseeable, has a reasonable likelihood of occurring and, if it were to occur, might materially adversely affect the general affairs,
business, operations, assets, condition (financial or otherwise) or results of operations or prospects of the Company and its subsidiaries taken as a whole; provided, however, that the following shall not be taken into account in determining a
“Material Adverse Event”: (a) any adverse change, event or effect that is directly attributable to conditions affecting the United States economy generally unless such conditions adversely affect the Company in a materially
disproportionate manner, and (b) any adverse change, event or effect that is directly attributable to conditions affecting the Company’s industry generally, unless such conditions adversely affect the Company in a materially disproportionate
manner. The party asserting that a Material Adverse Event has occurred shall have the burden of proof by a preponderance of the evidence with respect to any dispute regarding whether a change, event or effect is or is not “directly attributable
to” any of the foregoing. 
  
 1.8 The terms
“Register”, “Registered”, and “Registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act
(“Registration Statement”), and the declaration or ordering of the effectiveness of such Registration Statement. 
  
 1.9 “Registrable Securities” shall mean (a) all Common Stock not previously sold to the public and issued or
issuable upon conversion of any Convertible Securities purchased by or issued to the Investors, (b) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or
other distribution with respect to, or in exchange or replacement of the shares referenced in (a) above, excluding in the case of either (a) or (b) any Registrable Securities sold by a person in a transaction in which his, her or its Registration
rights under this Agreement are not assigned pursuant to the terms of this Agreement. 
  
 1.10 “Registration Expenses” shall mean all expenses other than underwriting discounts and commissions incurred by
the Company in complying with Sections 6 or 7 of this Agreement, including, without limitation, all federal and state registration, qualification, and filing fees, printing expenses, fees and disbursements of counsel for the Company and one 

  

 2 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
special counsel for all Holders (if different from counsel to the Company), blue sky fees and expenses, and the expense of any special audits incident to or
required by any such registration. 
  
 1.11
“Securities Act” shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
  
 1.12 “Selling Expenses” shall mean
all underwriting discounts and selling commissions applicable to the sale of Registrable Securities pursuant to this Agreement. 
  
 2. Financial Statements and Reports to Stockholders. The Company shall deliver to each Investor as soon as practicable after the end of each
fiscal year of the Company, and in any event within 90 days thereafter, an audited consolidated balance sheet of the Company as of the end of such year and audited consolidated statements of income, stockholders’ equity and cash flow for such
year, which year-end financial reports shall be in reasonable detail and shall be prepared in accordance with generally accepted accounting principles (“GAAP”) (except that such financial reports may not contain footnotes
required by GAAP) and accompanied by the opinion of independent public accountants of nationally recognized standing selected by the Company. In addition, the Company shall deliver to the Investors: (a) contemporaneously with delivery to holders of
Common Stock, a copy of each report of the Company delivered to holders of Common Stock and (b) an annual capitalization summary. 
  
 3. Additional Information. As long as an Investor (together with any affiliate) or its transferee holds at least 1,000,000 shares of Series
A Preferred Stock, Series B Preferred Stock and/or Series C Preferred Stock (or an equivalent number of shares consisting of Registrable Securities issued upon conversion of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred
Stock and/or a combination of such Registrable Securities and Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock), in each case as adjusted for recapitalizations, stock splits, stock dividends and the like, the Company
will deliver to such Investor: 
  
 (a) as soon as
practicable after the end of each of the first three quarters of any fiscal year, and in any event within 45 days thereafter, consolidated balance sheets of the Company as of the end of such quarter, and consolidated statements of income and cash
flow for such quarter and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles (other than for accompanying notes) and signed by the Chief Financial Officer or President of the Company certifying
that they fairly and, in all material respects, accurately present, as of their respective dates, the financial condition and results of operation of the Company, subject to changes resulting from year-end audit adjustment; 
  
 (b) as soon as practicable following submission to and
approval by the Board of Directors of the Company, but in no event later than 30 days prior to the end of each fiscal year, an operating budget and plan (the “Plan”) with respect to the next fiscal year and a summary of such
Plan together with any update of the Plan as such update is prepared; and 
  

 3 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 (c) such other information relating to the financial condition, business, prospects,
or corporate affairs of the Company as the Investor or any assignee of the Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this subsection (c) or any other subsection of Section 3
to provide information that the Company’s Board of Directors deems in good faith to be a trade secret or confidential information. 
  
 4. Inspection. The Company shall permit each Investor, at such Investor’s expense, to visit and inspect the Company’s properties,
to examine its books of account and records and to discuss the Company’s affairs, finances, and accounts with its officers, all at such reasonable times as may be requested reasonably in advance by each such Investor; provided, however, that
the Company shall not be obligated pursuant to this Section 4 to provide any information which it reasonably considers to be a trade secret or other confidential information. Unless assigned in accordance with Section 14, the rights of an Investor
under this Section 4 may not be assigned as part of such Investor’s sale of any of the Registrable Securities or Convertible Securities except with the consent of the Company. 
  
 5. Termination of Covenants. The covenants of the Company set forth in Sections 2, 3, and 4 shall be
terminated and be of no further force or effect upon the earliest of 
  
 5.1 immediately prior to the closing of the first underwritten public offering of the Common Stock of the Company, at a price per share not less than $5.00 per share (as adjusted for recapitalizations, stock splits,
stock dividends and the like) and with aggregate gross proceeds to the Company in excess of $30,000,000 (before deduction of underwriters commissions and expenses), that is effected pursuant to a Registration Statement filed with, and declared
effective by, the Commission under the Securities Act; 
  
 5.2 as to any Investor, at such time as such Investor no longer holds any shares of the capital stock of the Company; and 
  
 5.3 upon the effectiveness of a merger or consolidation of the Company with another entity if the Company is not the surviving corporation
and more than 50% of the equity voting interests of the Company is disposed of, or the sale by the Company or by one or more stockholders of equity or voting interests in the Company in a single offering or transaction or series of related
transactions after which at least 50% of the equity voting interests of the Company is controlled by persons that did not control such interests prior to such merger or consolidation; provided however, that a merger or consolidation with (a) a
subsidiary which effects a mere change in the form or domicile of the Company without changing the respective stock holdings of the Stockholders or (b) any entity of which the Stockholders other than the Investors own in the aggregate more than 50%
of the equity interest of the surviving entity, shall not terminate this Agreement even if the Corporation is not the surviving corporation. 
  
 6. Demand Registration. 
  
 6.1 Request for Registration on Form Other Than Form S-3. Subject to the terms of this Agreement, in the event that the
Company shall receive from the Initiating Holders at any time after the earlier of (a) May 17, 2007 or (b) six months after the closing of the 

  

 4 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
Company’s initial public offering of shares of Common Stock under a Registration Statement, a written request that the Company effect any Registration
with respect to all or a part of the Registrable Securities on a form other than Form S-3 for an offering of at least $5,000,000 net of Selling Expenses (provided, however, that if the Company has not consummated an initial public offering prior to
such demand, this demand right pursuant to this Section 6.1 may be exercised only for an offering of at least $30,000,000, net of Selling Expenses), the Company shall (i) promptly give written notice of the proposed Registration to all other Holders
and (ii) as soon as practicable, use all reasonable efforts to effect Registration of the Registrable Securities specified in such request, together with any Registrable Securities of any Holder joining in such request as are specified in a written
request given within 20 days after written notice from the Company. The Company shall not be obligated to take any action to effect any such Registration pursuant to this Section 6.1 (A) under any of the circumstances described in Section 6.3 or (B)
after the Company has effected two such Registrations pursuant to this Section 6.1 and such Registrations have been declared effective. 
  
 6.2 Request for Registration on Form S-3. If a Holder or Holders of the outstanding Registrable Securities request that the
Company file a Registration Statement on Form S-3 (or any successor form to Form S-3) for a public offering of shares of Registrable Securities the reasonably anticipated aggregate price to the public of which, net of Selling Expenses, would not be
less than $1,000,000, and the Company is a registrant entitled to use Form S-3 to register the Registrable Securities for such an offering, the Company shall use all reasonable efforts to effect Registration of the Registrable Securities on such
form; provided, however, that the Company shall not be required to (a) effect more than two Registrations pursuant to this Section 6.2 or (b) take any action to effect any such Registration pursuant to this Section 6.2 under any of the circumstances
described in Section 6.3. The substantive provisions of Section 6.5 shall be applicable to each Registration initiated under this Section 6.2. 
  
 6.3 Right of Deferral. Notwithstanding the foregoing, the Company shall not be obligated to file any Registration Statement
pursuant to this Section 6: 
  
 (a) if the
Company, within 30 days of the receipt of the request of the Initiating Holders, gives notice of its bona fide intention to effect the filing of a Registration Statement with the Commission within 90 days of receipt of such request (other than to a
Registration of securities for a transaction subject to Rule 145 promulgated under the Securities Act (“Rule 145”) or with respect to an employee benefit plan), provided that the Company is actively employing all reasonable efforts to
cause such Registration Statement to become effective; 
  
 (b) within six months immediately prior to and within six months immediately following the effective date of any Registration Statement pertaining to the securities of the Company (other than a registration of securities for a transaction
subject to Rule 145 or with respect to an employee benefit plan); or 
  
 (c) if the Company shall furnish to such Holders a certificate signed by the President of the Company stating that, in the good faith judgment of the Board of Directors, it would be seriously detrimental to the
Company or its stockholders for a Registration Statement to be filed in the near future, in which case the Company’s obligation to use all 

  

 5 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
reasonable efforts to file a Registration Statement shall be deferred for a period not to exceed 90 days from the receipt of the request by such Holder to
file such Registration Statement; provided, however, that the Company shall not exercise the right contained in this paragraph (d) more than once in any 12 month period. 
  
 6.4 Registration of Other Securities in Demand Registration. Any Registration Statement filed
pursuant to the request of the Initiating Holders under this Section 6 may, subject to the provisions of Section 6.5, include securities of the Company other than Registrable Securities. 
  
 6.5 Underwriting in Demand Registration. 
  
 (a) Notice of Underwriting. If the Initiating
Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 6, and the Company shall include such information
in the written notice referred to in Section 6.1 or 6.3. The right of any Holder to Registration pursuant to Section 6 shall be conditioned upon such Holder’s agreement to participate in such underwriting and the inclusion of such Holder’s
Registrable Securities in the underwriting. 
  
 (b) Inclusion of Other Holders in Demand Registration. If the Company, officers or directors of the Company holding Common Stock other than Registrable Securities, or holders of securities other than Registrable Securities,
request inclusion in such Registration, the Initiating Holders, to the extent they deem advisable and consistent with the goals of such Registration, may, in their sole discretion, on behalf of all Holders, offer to any or all of the Company, such
officers or directors, and such holders of securities other than Registrable Securities that such securities other than Registrable Securities be included in the underwriting and may condition such offer on the acceptance by such persons of the
terms of this Section 6. If, however, the number of shares so included by the Company exceeds the number of shares of Registrable Securities included by all Holders, such Registration shall be treated as governed by Section 7 hereof rather than
Section 6, and it shall not count as a Registration for purposes of Section 6.1 hereof. 
  
 (c) Selection of Underwriter in Demand Registration. The Company shall (together with all Holders proposing to distribute
their securities through such underwriting) enter into an underwriting agreement with the representative (“Underwriter’s Representative”) of the underwriter or underwriters selected for such underwriting by the Holders
of a majority of the Registrable Securities being registered by the Initiating Holders and agreed to by the Company. 
  
 (d) Marketing Limitation in Demand Registration. If the Underwriter’s Representative advises the Initiating Holders in
writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of the persons proposing to sell securities pursuant to the
Registration) require a limitation of the number of shares to be underwritten, then (i) first, the Common Stock (other than Registrable Securities) held by officers or directors of the Company, (ii) second, the securities other than Registrable
Securities, 

  

 6 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
and (iii) third, the securities requested to be registered by the Company, shall be excluded from such Registration to the extent required by such
limitation. If a limitation of the number of shares is still required, the Initiating Holders shall so advise all Holders and the number of shares of Registrable Securities that may be included in the Registration and underwriting shall be allocated
among all Holders in proportion, as nearly as practicable, to the respective amounts of Registrable Securities entitled to inclusion in such Registration held by such Holders at the time of filing the Registration Statement. No Registrable
Securities or other securities excluded from the underwriting by reason of this Section 6.5(d) shall be included in such Registration Statement. 
  
 (e) Right of Withdrawal in Demand Registration. If any Holder of Registrable Securities, or a holder of other securities
entitled (upon request) to be included in such Registration, disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company, the Underwriter’s Representative and the Initiating Holders
delivered at least ten business days prior to the effective date of the Registration Statement. The securities so withdrawn shall also be withdrawn from the Registration Statement. 
  
 7. Piggyback Registration. 
  
 7.1 Notice of Piggyback Registration and Inclusion of Registrable Securities. Subject to the
terms of this Agreement, if the Company decides to Register any of its Common Stock (either for its own account or the account of a security holder or holders exercising their respective demand registration rights) on a form that would be suitable
for a registration involving Registrable Securities (other than to a Registration of securities for a transaction subject to Rule 145 or with respect to an employee benefit plan), the Company will: (i) promptly give each Holder written notice
thereof (which shall include a list of the jurisdictions in which the Company intends to attempt to qualify such securities under the applicable Blue Sky or other state securities laws) and (ii) include in such Registration (and any related
qualification under Blue Sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request delivered to the Company by any Holder within 20 days after delivery of such written
notice from the Company. 
  
 7.2 Underwriting in Piggyback
Registration. 
  
 (a) Notice of
Underwriting in Piggyback Registration. If the Registration of which the Company gives notice is for a Registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given
pursuant to Section 7.1. In such event, the right of any Holder to Registration shall be conditioned upon such underwriting and the inclusion of such Holder’s Registrable Securities in such underwriting to the extent provided in this Section 7.
All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders distributing their securities through such underwriting) enter into an underwriting agreement with the
Underwriter’s Representative for such offering. The Holders shall have no right to participate in the selection of the underwriters for an offering pursuant to this Section 7. 
  

 7 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 (b) Marketing Limitation in Piggyback Registration. If the
Underwriter’s Representative advises the Company in writing that market factors (including, without limitation, the aggregate number of shares of Common Stock requested to be Registered, the general condition of the market, and the status of
the persons proposing to sell securities pursuant to the Registration) require a limitation of the number of shares to be underwritten, the Company (subject to the allocation priority set forth in Section 7.2(c)) may: 
  
 (i) in the case of the Company’s initial Registered
public offering, exclude some or all Registrable Securities from such registration and underwriting; and 
  
 (ii) in the case of any Registered public offering subsequent to the initial public offering, limit the number of shares of Registrable
Securities to be included in such Registration and underwriting to not less than 30% of the securities included in such Registration. 
  
 (c) Allocation of Shares in Piggyback Registration. If the Underwriter’s Representative limits the number of shares to
be included in a Registration pursuant to Section 7.2(b), the number of shares to be included in such Registration shall be allocated (subject to Section 7.2(b)) in the following manner: The shares (other than Registrable Securities) held by
officers or directors of the Company shall be excluded from such registration and underwriting to the extent required by such limitation. If a limitation of the number of shares is still required after such exclusion, the number of shares that may
be included in the Registration and underwriting by selling stockholders shall be allocated pro rata among all Holders requesting that their securities be included in such Registration until all shares so requested to be included by such Holders are
included in the Registration; provided, however, that to the extent that the Holders would otherwise be entitled to include more shares in such Registration than can be included, then the number of shares shall be allocated among the Holders in
proportion, as nearly as practicable, to the respective amounts of securities (including Registrable Securities) that such Holders would otherwise be entitled to include in such Registration. To the extent that shares remain that may be allocated
after such allocation to the Holders, then those holders of securities (other than Registrable Securities) who request and are legally entitled to include their securities in such Registration may include their shares in proportion, as nearly as
practicable, to the respective amounts of securities (including Registrable Securities) which those holders would otherwise be entitled to include in such Registration. No Registrable Securities or other securities excluded from the underwriting by
reason of this Section 7.2(c) shall be included in the Registration Statement. 
  
 (d) Withdrawal in Piggyback Registration. If any Holder disapproves of the terms of any such underwriting, such person may
elect to withdraw therefrom by written notice to the Company and the Underwriter’s Representative delivered at least ten business days prior to the effective date of the Registration Statement. Any Registrable Securities or other securities
excluded or withdrawn from such underwriting shall be withdrawn from such Registration. 
  
 8. Expenses of Registration. All Registration Expenses incurred in connection with up to two Registrations pursuant to Section 6.1, up to two Registrations pursuant to Section 6.2 and unlimited
Registrations pursuant to Section 7.2, including the reasonable fees and expenses 

  

 8 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
of one legal counsel for the holders of the securities so registered, shall be borne by the Company. All Registration Expenses incurred in connection with
any other Registration, qualification, or compliance, shall be apportioned among the Holders and other holders of the securities so registered on the basis of the number of shares so registered. 
  
 9. Termination of Registration Rights. The rights to cause the
Company to register securities granted under Sections 6 and 7 of this Agreement and to receive notices pursuant to Section 7 of this Agreement shall terminate, with respect to each Holder, on the earlier of (i) the date three years after the closing
date of the Company’s initial public offering of securities pursuant to a Registration Statement, (ii) with respect to each Holder if such Holder is eligible to sell all of such Holder’s Registrable Securities under Rule 144 of the
Securities Act within any three month period without volume limitations without relying on Rule 144(k) thereunder, or (iii) with respect to each Holder if such Holder is eligible to sell all of such Holder’s Registrable Securities under Rule
144(k) thereunder; provided, however, that such Holder’s rights shall not terminate pursuant to clause (iii) if such Holder owns more than 1% of the Company’s outstanding Common Stock (including, for this purpose, common stock issuable
upon conversion of the Company’s outstanding Preferred Stock). 
  
 10. Registration Procedures and Obligations. Whenever required under this Agreement to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
  
 (a) Prepare and file with the Commission a Registration
Statement with respect to such Registrable Securities and use its reasonable efforts to cause such Registration Statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder,
keep such Registration Statement effective for up to 90 days. 
  
 (b) Prepare and file as expeditiously as reasonably practicable with the Commission such amendments and supplements to such Registration Statement and the prospectus used in connection with such registration statement
as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement. 
  
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in
conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
  
 (d) Use its reasonable efforts to register and qualify the
securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business in any jurisdiction where it is not so qualified or to file a general consent to service of process in any such states or jurisdictions, and provided further that in the event any jurisdiction in which the
securities shall be qualified imposes a non-waivable requirement that expenses incurred in 

  

 9 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
connection with the qualification of the securities be borne by selling stockholders, such expenses shall be payable pro rata by selling stockholders.

  
 (e) In the event of any underwritten public
offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its
obligations under such an agreement. 
  
 (f)
Notify each Holder of Registrable Securities covered by such Registration Statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus
included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of
the circumstances then existing. 
  
 (g) Provide
a transfer agent and registrar for all Registrable Securities registered pursuant to such Registration Statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

 
 (h) Furnish, at the request of any Holder requesting
registration of Registrable Securities pursuant to this Agreement, on the date that such Registrable Securities are delivered for sale in connection with a registration pursuant to this Agreement, (i) an opinion, dated such date, of the counsel
representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters (with a copy provided to each holder of Registrable Securities) in an underwritten public offering, and (ii) a letter dated
such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters
(with a copy provided to each holder of Registrable Securities). 
  
 (i) Use all reasonable efforts to list the Registrable Securities covered by such registration statement with Nasdaq or any securities exchange on which the Common Stock of the Company is then listed, or Nasdaq or
such securities exchange as shall be selected by the Company, or, if the Company fails to make an application to so list within 30 days of a request for the same by the Investors in connection with a Qualified Public Offering, as defined below, the
Investors may determine the place of listing, subject to qualification by the Company to list its shares thereon. 
  
 (j) Notify each seller of Registrable Securities under such registration statement of (i) the effectiveness of such registration
statement, (ii) the filing of any post-effective amendments to such registration statement, or (iii) the filing of a supplement to such registration statement. 
  

(k) Make available for inspection upon reasonable notice during the Company’s regular business hours by each seller of Registrable
Securities, any underwriter participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such seller or underwriter, all material financial and other 

  

 10 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
records, pertinent corporate documents and properties of the Company reasonably requested to be inspected by any such seller, underwriter, attorney,
accountant or agent in connection with such registration statement, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in
connection with such registration statement. 
  
 11.
Information Furnished by Holder. It shall be a condition precedent of the Company’s obligations under this Agreement that each Holder of Registrable Securities included in any Registration furnish to the Company such information
regarding such Holder and the distribution proposed by such Holder or Holders as the Company may reasonably request. 
  
 12. Indemnification. 
  
 12.1 Company’s Indemnification of Holders. To the extent permitted by law, the Company will indemnify each Holder, each
of its officers, directors, and constituent partners and each person controlling such Holder, with respect to which Registration, qualification, or compliance of Registrable Securities has been effected pursuant to this Agreement, and each
underwriter, if any, and each person who controls any underwriter against all claims, losses, damages, liabilities, or actions in respect thereof (collectively, “Damages”) to the extent such Damages arise out of or are based
upon any untrue statement (or alleged untrue statement) of a material fact contained in any prospectus or other document (including any related Registration Statement) incident to any such Registration, qualification, or compliance, or are based on
any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, or any violation by the Company of
any rule or regulation promulgated under the Securities Act applicable to the Company and relating to action or inaction required of the Company in connection with any such Registration, qualification, or compliance; and the Company will reimburse
each such Holder, each such underwriter, and each person who controls any such Holder or underwriter, for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or
action; provided, however, that the indemnity contained in this Section 12.1 shall not apply to amounts paid in settlement of any such Damages if settlement is effected without the consent of the Company (which consent shall not unreasonably be
withheld); and provided, further, that the Company will not be liable in any such case to the extent that any such Damages arise out of or are based upon (a) any untrue statement or omission based upon written information furnished to the Company by
such Holder, underwriter, or controlling person and stated to be for use in connection with the offering of securities of the Company or (b) the gross negligence or willful misconduct of such Holder, underwriter, or controlling person. 

 
 12.2 Holder’s Indemnification of
Company. To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such Registration, qualification or, compliance is being effected pursuant to this Agreement,
indemnify the Company, each of its directors, officers and employees, each underwriter, if any, of the Company’s securities covered by such a Registration Statement, each person who controls the Company or such underwriter within the meaning of
the Securities Act, and each other such Holder, each of its officers, directors, and constituent partners, and each person controlling such other Holder, against all Damages arising out of or based upon any 

  

 11 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
untrue statement (or alleged untrue statement) of a material fact contained in any such Registration Statement, prospectus, offering circular, or other
document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, or any violation by
such Holder of any rule or regulation promulgated under the Securities Act applicable to such Holder and relating to action or inaction required of such Holder in connection with any such Registration, qualification, or compliance, and will
reimburse the Company, such Holders, such directors, officers, partners, persons, underwriters or control persons for any legal and any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage,
liability, or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such Registration Statement, prospectus, offering circular, or other
document in reliance upon and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use in connection with the offering of securities of the Company, provided, however, that the indemnity
contained in this Section 12.2 shall not apply (a) to amounts paid in settlement of any such Damages if settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld) and (b) to the extent that any such
Damages arise out of or are based upon the gross negligence or willful misconduct of the Company or such other Holders, directors, officers, partners, persons, underwriters or control persons; and provided, further, that each Holder’s liability
under this Section 12.2 shall not exceed such Holder’s net proceeds from the offering of securities made in connection with such Registration. 
  
 12.3 Indemnification Procedure. Promptly after receipt by an indemnified party under this Section 12 of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 12, notify the indemnifying party in writing of the commencement thereof and generally summarize
such action. The indemnifying party shall have the right to participate in and to assume the defense of such claim; provided, however, that the indemnifying party shall be entitled to select counsel for the defense of such claim with the approval of
any parties entitled to indemnification, which approval shall not be unreasonably withheld; provided further, however, that if either party reasonably determines that there may be a conflict between the position of the Company and the Investors in
conducting the defense of such action, suit, or proceeding by reason of recognized claims for indemnity under this Section 12, then counsel for such party shall be entitled to conduct the defense to the extent reasonably determined by such counsel
to be necessary to protect the interest of such party. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to the ability of the indemnifying party to defend such action, shall relieve such
indemnifying party, to the extent so prejudiced, of any liability to the indemnified party under this Section 12, but the omission so to notify the indemnifying party will not relieve such party of any liability that such party may have to any
indemnified party otherwise than under this Section 12. 
  
 12.4 Contribution. If the indemnification provided for in this Section 12 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any Damages referred to
therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such Damages in such proportion as is appropriate to reflect the
relative fault 

  

 12 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such
Damages as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a
material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or
prevent such statement or omission. 
  
 12.5
Conflicts. Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into by the Company and the Selling Stockholders in connection with the
underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
  
 12.6 Survival of Obligations. The obligations of the Company and Holders under this Section 12 shall survive the completion
of any offering of Registrable Securities in a registration statement under this Agreement or otherwise. 
  
 13. Limitations on Registration Rights Granted to Other Securities. From and after the date of this Agreement, for so long as 2,479,136
shares of Convertible Securities remain issued and outstanding (as adjusted for recapitalizations, stock splits, stock dividends and the like), the Company shall not enter into any agreement with any holder or prospective holder of any securities of
the Company providing for the granting to such holder of any Registration rights having priority over, or pari passu with, the registration rights granted to the holders of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred
Stock pursuant to this Agreement, without the consent of the Holders of not less than 66-2/3% of the Convertible Securities then outstanding. Any additional holders must be added as parties to this Agreement with regard to any or all securities of
the Company held by them and any such additional parties shall execute a counterpart of this Agreement, and upon execution by such additional parties and by the Company, shall be considered Investors for all purposes of this Agreement. The
additional parties and the additional Registrable Securities shall be identified in an amendment to Exhibit A hereto. 
  
 14. Transfer of Rights. The rights to information under Sections 2, 3 and 4 and the right to cause the Company to Register securities
granted by the Company to the Investors under Sections 6 and 7, may be assigned by any Holder to a transferee or assignee of at least 1,000,000 shares of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock or Registrable
Securities not sold to the public; provided, however, that the Company must receive written notice prior to the time of such transfer, stating the name and address of such transferee or assignee and identifying the securities with respect to which
such rights are being assigned. 
  
 15. Market
Stand-off. Each Holder hereby agrees that, if so requested by the Company and the Underwriter’s Representative (if any) in connection with the Company’s initial public offering, such Holder shall not sell, make any short sale of,
loan, grant any option for the purchase of, or otherwise transfer or dispose of any Registrable Securities or other securities of the Company without the prior written consent of the Company and the Underwriter’s 

  

 13 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
Representative for such period of time (not to exceed 180 days) following the effective date of a Registration Statement of the Company filed under the
Securities Act as may be requested by the Underwriter’s Representative. The obligations of Holders under this Section 15 shall be conditioned upon similar agreements being in effect with each other stockholder who is an officer, director, or 1%
stockholder of the Company. 
  
 16. No-Action Letter or
Opinion of Counsel in Lieu of Registration; Conversion of Preferred Stock. Notwithstanding anything else in this Agreement, if the Company shall have obtained from the Commission a “no-action” letter in which the Commission has
indicated that it will take no action if, without Registration under the Securities Act, any Holder disposes of Registrable Securities covered by any request for Registration made under this Section in the specific manner in which such Holder
proposes to dispose of the Registrable Securities included in such request (including, without limitation, inclusion of such Registrable Securities in an underwriting initiated by either the Company or the Holders) and that such Registrable
Securities may be sold to the public without Registration, or if in the opinion of counsel for the Company concurred in by counsel for such Holder, which concurrence shall not be unreasonably withheld, no Registration under the Securities Act is
required in connection with such disposition and that such Registrable Securities may be sold to the public without Registration, the Registrable Securities included in such request shall not be eligible for Registration under this Agreement;
provided, however, that any Registrable Securities not so disposed of shall be eligible for Registration in accordance with the terms of this Agreement with respect to other proposed dispositions to which this Section 16 does not apply. The
Registration rights of the Holders of the Registrable Securities set forth in this Agreement are conditioned upon the conversion of the Registrable Securities with respect to which registration is sought into Common Stock prior to the effective date
of the Registration Statement. 
  
 17. Reports Under the
Exchange Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the Commission that may at any time permit a Holder to sell securities of the
Company to the public without Registration or pursuant to a registration on Form S-3, the Company agrees to: 
  
 (a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times after 90 days after
the effective date of the first Registration Statement filed by the Company for the offering of its securities to the public; 
  
 (b) take such action as is reasonably necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities,
subject to Section 6.2, such action to be taken as soon as practicable after the end of the fiscal year in which the first Registration Statement filed by the Company for the offering of its securities to the general public is declared effective;

  
 (c) file with the Commission in a timely
manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
  
 (d) furnish to any Holder, so long as the Holder owns any Registrable Securities, promptly upon request (i) a written statement by the
Company that it has complied 

  

 14 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
with the reporting requirements of Rule 144 (at any time after 90 days after the effective date of the first Registration Statement filed by the Company),
the Securities Act, and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a
copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the
Commission which permits the selling of any such securities without Registration or pursuant to such form. 
  
 18. Amendment of Prior Rights Agreement. Effective and contingent upon execution of this Agreement by the Company and Series A Investors
holding at least a majority of the outstanding Registrable Securities subject to the Prior Rights Agreement (and, with respect to Section 13 of the Prior Rights Agreement, by the Company, Series A Investors and Series B Investors holding at least
60% of the Convertible Securities and Registrable Securities outstanding), and upon closing of the transactions contemplated by the Purchase Agreement, the Prior Rights Agreement is hereby amended and restated in its entirety to read as set forth in
this Agreement, and the Company and the Investors hereby agree to be bound by the provisions hereof as the sole agreement of the Company and the Investors with respect to the subject matter hereof. 
  
 19. Aggregation of Stock. For the purpose of determining the
availability of any rights under this Agreement, all shares of Company capital stock held or acquired by any Investor shall be aggregated together with all shares of Company capital stock held or acquired by such Investor’s partners and
affiliates and any corporation, trust, partnership, limited liability corporation or partnership, or other form of business entity that is an investment fund that has the same or an affiliated investment manager and/or advisory service provider.

  
 20. Miscellaneous. 
  
 20.1 Governing Law. This Agreement shall be
governed by, and construed in accordance with, the laws of the State of Delaware, excluding those laws that direct the application of the laws of another jurisdiction. 
  
 20.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 20.3 Headings. The headings of the Sections of this Agreement are for convenience and shall not by themselves determine the
interpretation of this Agreement. 
  
 20.4
Notices. Any notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively given upon personal delivery or delivery by courier, or on the first business day after transmission if sent by
confirmed facsimile transmission or electronic mail transmission, or five days after deposit in the United States mail, by registered or certified mail, postage prepaid, addressed (i) if to the Company, as set forth below the Company’s name on
the signature page of this Agreement, and (ii) if to an Investor, at such Investor’s address as set forth below such Investor’s address on the signature page to this 

  

 15 

 Corus Pharma, Inc 
 Amended and Restated Information and Registration Rights Agreement 
  

 
Agreement, or at such other address as the Company or such Investor may designate by 10 days’ advance written notice to the other parties hereto.

  
 20.5 Amendment of Agreement.
Any provision of this Agreement may be amended only by a written instrument signed by the Company and by persons holding 66-2/3% of the Registrable Securities as defined in Section 1 of this Agreement (calculated on an as-converted basis); provided,
however, that the Company may amend this Agreement at any time and from time to time without the consent of any holder of Registrable Securities solely to add additional purchasers of Series C Preferred Stock as “Series C Investors.”

  
 20.6 Severability. If any one
or more of the covenants, agreements, provisions or terms of this Agreement shall be for any reason whatsoever held invalid, the invalidity of any such covenant, agreement, provision or term of this Agreement shall in no way affect the validity or
enforceability of the other provisions of this Agreement; provided, that if the invalidity of any covenant, agreement or provision shall deprive any party of the economic benefit intended to be conferred by this Agreement, the parties shall
negotiate in good faith to amend the Agreement in such a matter that the economic effect of the Agreement, as amended, is, as nearly as possible, the same as the economic effect of this Agreement. 
  
 20.7 Entire Agreement; Successors and Assigns.
This Agreement and the Purchase Agreement constitute the entire contract among the Company and the Investors relative to the subject matter hereof. Any previous or contemporaneous agreement, discussion, understanding or correspondence, oral or
written, between the Company and any Investor concerning Registration rights is superseded by this Agreement. Subject to the exceptions specifically set forth in this Agreement, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective executors, administrators, heirs, successor, and assigns of the parties. 
  
 [Signature Pages Follow] 
  

 16 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above
written. 
  

											
	Company:	 	 	 	 CORUS PHARMA, INC.,
 a Delaware corporation

					
	 	 	 	 	 	 	By:	 	 /s/ A. Bruce Montgomery, M.D.

	 	 	 	 	 	 	 Name:
	 	 A. Bruce Montgomery, M.D.

	 	 	 	 	 	 	 Title:
	 	 President

					
	 	 	 	 	 	 	 Address:
	 	 2025 First Avenue, Suite 800
 Seattle, WA 98121

	 	 	 	 	 	 	 Fax:
	 	 

											
			
	Investors:	 	 	 	BEAR STEARNS HEALTH INNOVENTURES, L.P.
					
	 	 	 	 	 	 	By:	 	 Bear Stearns Health Innoventures
 Management,
LLC
 Its General Partner

						
	 	 	 	 	 	 	 	 	 By:
	 	 /s/ Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	 Name: Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	Title: Managing Partner

											
					
	 	 	 	 	 	 	 Address:
	 	 383 Madison Avenue, 28th Floor
 New York, NY 10179

	 	 	 	 	 	 	 Fax:
	 	 	 	 (212) 881-1378

			
	 	 	 	 	BEAR STEARNS HEALTH INNOVENTURES OFFSHORE, L.P.
					
	 	 	 	 	 	 	By:	 	 Bear Stearns Health Innoventures
 Management, LLC
 Its General Partner

						
	 	 	 	 	 	 	 	 	 By:
	 	 /s/ Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	 Name: Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	Title: Managing Partner

											
					
	 	 	 	 	 	 	 Address:
	 	 383 Madison Avenue, 28th Floor
 New York, NY 10179

	 	 	 	 	 	 	 Fax:
	 	 	 	 (212) 881-1378

  
 *Signature Page
to Information and Registration Rights Agreement* 
  

											
	 	 	 	 	BSHI MEMBERS, L.L.C.
					
	 	 	 	 	 	 	By:	 	 Bear Stearns Health Innoventures
 Management,
LLC
 Its General Partner

						
	 	 	 	 	 	 	 	 	 By:
	 	 /s/ Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	 Name: Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	Title: Managing Partner
					
	 	 	 	 	 	 	 Address:
	 	 383 Madison Avenue, 28th Floor
 New York, NY 10179

	 	 	 	 	 	 	 Fax:
	 	 	 	 (212) 881-1378

			
	 	 	 	 	BEAR STEARNS HEALTH INNOVENTURES EMPLOYEE FUND, L.P.
					
	 	 	 	 	 	 	By:	 	 Bear Stearns Health Innoventures
 Management, LLC
 Its General Partner

						
	 	 	 	 	 	 	 	 	 By:
	 	 /s/ Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	 Name: Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	Title: Managing Partner
					
	 	 	 	 	 	 	 Address:
	 	 383 Madison Avenue, 28th Floor
 New York, NY 10179

	 	 	 	 	 	 	 Fax:
	 	 	 	 (212) 881-1378

			
	 	 	 	 	BX, L.P.
					
	 	 	 	 	 	 	By:	 	 Bear Stearns Health Innoventures
 Management, LLC
 Its General Partner

						
	 	 	 	 	 	 	 	 	 By:
	 	 /s/ Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	 Name: Elizabeth A. Czerepak

	 	 	 	 	 	 	 	 	 	 	Title: Managing Partner
					
	 	 	 	 	 	 	 Address:
	 	 383 Madison Avenue, 28th Floor
 New York, NY 10179

	 	 	 	 	 	 	 Fax:
	 	 	 	 (212) 881-1378

  
 *Signature Page
to Information and Registration Rights Agreement* 
  

					
	T. ROWE PRICE HEALTH SCIENCES FUND, INC.
		
	By:	 	 /s/ Kris Jenner

	 	 	 Name:
	 	 Kris Jenner

	 	 	 Its:
	 	 Vice President

		
	 Address:
	 	 100 East Pratt Street

	 	 	 	 	 Baltimore, MD 21202

	 	 	 	 	 Attn: Darrell N. Braman

	 Fax:
	 	 410-345-6575

  

					
	SUNAMERICA LIFE INSURANCE COMPANY
		
	By:	 	 /s/ Marc Gamsin

	 	 	 Name:
	 	 Marc Gamsin

	 	 	 Its:
	 	 Executive Vice President

		
	 Address:
	 	 1 SunAmerica Center, 38th Floor

	 	 	 	 	 Los Angeles, CA 90067

	 Fax:
	 	 310-772-6705

  

					
	H & Q HEALTHCARE INVESTORS
		
	By:	 	 /s/ Daniel R. Omstead

	 	 	 Name:
	 	 Daniel R. Omstead, EngScD

	 	 	 Title:
	 	 
		
	 Address:
	 	 30 Rowes Wharf, Suite 4300

	 	 	 	 	 Boston, MA 02110-3328

	 Fax:
	 	 617-772-8577

  
 The term H&Q Healthcare
Investors is the designation of the Trustees for the time being under an Amended and Restated Declaration of Trust dated April 21, 1987, as amended, and all persons dealing with H&Q Healthcare Investors must look solely to the trust property for
the enforcement of any claim against H&Q Healthcare Investors, as neither the Trustees, officers nor shareholder assume any personal liability for the obligations entered into on behalf of H&Q Healthcare Investors. 
  
 *Signature Page to Information and Registration Rights Agreement*

  

					
	H & Q LIFE SCIENCES INVESTORS
		
	By:	 	 /s/ Daniel R. Omstead

	 	 	 Name:
	 	 Daniel R. Omstead, EngScD

	 	 	 Title:
	 	 
		
	 Address:
	 	 30 Rowes Wharf, Suite 4300

	 	 	 	 	 Boston, MA 02110-3328

	 Fax:
	 	 617-772-8577

  
 The term H&Q Life Sciences
Investors is the designation of the Trustees for the time being under a Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with H&Q Life Sciences Investors must look solely to the trust property for the enforcement
of any claims against H&Q Life Sciences Investors, a neither the Trustees, officers nor shareholder assume any personal liability for the obligations entered into on behalf of H&Q Life Sciences Investors. 
  

					
	MPM BIOEQUITIES FUND GMBH & CO. KG
		
	By:	 	 MPM BioEquities GP, L.P., in its

	 	 	 capacity as the Managing Limited Partner

		
	By:	 	 MPM BioEquities GP LLC, its General Partner

		
	 By:
	 	 /s/ Kurt H. von Emster

	 	 	 Kurt H. von Emster

	 	 	 Manager

		
	 Address:
	 	 601 Gateway Blvd., Suite 350

	 	 	 	 	 South San Francisco, CA 94080

	 Fax:
	 	 650-553-3335

  

					
	MPM BIOEQUITIES MASTER FUND LP
		
	By:	 	 MPM BioEquities GP, L.P., its General Partner

		
	By:	 	 MPM BioEquities GP LLC, its General Partner

		
	 By:
	 	 /s/ Kurt H. von Emster

	 	 	 Kurt H. von Emster

	 	 	 Manager

		
	 Address:
	 	 601 Gateway Blvd., Suite 350

	 	 	 	 	 South San Francisco, CA 94080

	 Fax:
	 	 650-553-3335

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

					
	CARNEGIE FUND II, BIOTECH BRIDGE SUB FUND
		
	By:	 	 /s/ V. Gruselle / B. Frerejean

	 	 	 Name:
	 	 V. Gruselle / B. Frerejean

	 	 	 Its:
	 	 Director / Director

		
	 Address:
	 	 5, Place de la Gare

	 	 	 	 	 Luxembourg, L-1750

	 	 	 	 	 Luxembourg

	 Fax:
	 	 46858869137

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

					
	CRAMER HOLDINGS LLC
		
	By:	 	 /s/ Kirby L. Cramer

	 	 	 Name:
	 	 Kirby L. Cramer

	 	 	 Its:
	 	 Member

		
	 Address:
	 	 243 Lake Ave. West, Suite 200

	 	 	 Kirkland, WA 98033

	 Fax:
	 	 

  

					
	COURTNEY M. CRAMER
		
	 	 	 /s/ Courtney M Cramer

		
	 Address:
	 	 19630 SE 184th Street

	 	 	 	 	 Renton, WA 98058

	 Fax:
	 	 

  

					
	KIRBY L. CRAMER, JR.
		
	 	 	 /s/ Kirby L. Cramer, Jr.

		
	 Address:
	 	 26 Rolling View Lane

	 	 	 	 	 Fallbrook, CA 92028

	 Fax:
	 	 

  

					
	KIMBERLY C. DYER
		
	 	 	 /s/ Kimberly C. Dyer

		
	 Address:
	 	 11817 Turtle Springs Lane

	 	 	 	 	 Northridge, CA 91326

	 Fax:
	 	 

  

					
	ELIZABETH E. RICHARD
		
	 	 	 /s/ Elizabeth C. Richard

		
	 Address:
	 	 440 Highcroft Road

	 	 	 	 	 Wayzata, MN 55391

	 Fax:
	 	 

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	NOVO A/S
		
	 By:
	 	 /s/ Ulrik Spork

	 Name:
	 	 Ulrik Spork

	 Title:
	 	 Chief Investment Officer

		
	 Address:
	 	 Krogshoejvej 41

	 	 	 DK 2880 Bagsvaerd

	 	 	 Denmark

	 Fax:
	 	 011 (45) 4442-1440

  

			
	J.P. MORGAN PARTNERS (SBIC), LLC
		
	 By:
	 	 /s/ Ronald A. Ferguson

	 Name:
	 	 Rodney A. Ferguson

	 Title:
	 	 Managing Director

		
	 Address:
	 	 50 California, 29th Floor

	 	 	 San Francisco, CA 94111

	 Fax:
	 	 (415) 591-1235

  

			
	J.P. MORGAN PARTNERS GLOBAL INVESTORS
(SBIC), LLC
		
	 By:
	 	 /s/ Ronald A. Ferguson

	 Name:
	 	 Rodney A. Ferguson

	 Title:
	 	 Managing Director

		
	 Address:
	 	 50 California, 29th Floor

	 	 	 San Francisco, CA 94111

	 Fax:
	 	 (415) 591-1235

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

					
	MDS LIFE SCIENCES TECHNOLOGY FUND II NC LIMITED PARTNERSHIP
		
	By:	 	 MDS LSTF II (NCGP) INC.
 its General Partner

			
	 	 	 By:
	 	 /s/ G. Bedell / Greg Gubitz

	 	 	 Name:
	 	 G. Bedell / Greg Gubitz

	 	 	 Title:
	 	 Secretary / Vice-President

			
	 	 	 Address:
	 	 100 International Blvd.

	 	 	 	 	 Toronto, Ontario

	 	 	 	 	 M9W 6J6

	 	 	 Fax:
	 	 

  

					
	MDS LIFE SCIENCES TECHNOLOGY FUND QUEBEC LIMITED
PARTNERSHIP
		
	By:	 	 MDS LSTF II (QGP) INC.
 its General Partner

			
	 	 	 By:
	 	 /s/ G. Bedell / Greg Gubitz

	 	 	 Name:
	 	 G. Bedell / Greg Gubitz

	 	 	 Title:
	 	 Secretary / Vice-President

			
	 	 	 Address:
	 	 2000 Peel Street, Suite 560

	 	 	 	 	 Montreal, Quebec

	 	 	 	 	 H3A 2W5

	 	 	 Fax:
	 	 
	
	 Copy to:

	 Legal Department

	 MDS Capital Corp.

	 100 International Blvd.

	 Toronto, Ontario M9W 6J6

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

					
	MLII CO-INVESTMENT FUND NC LIMITED PARTNERSHIP
		
	By:	 	 MLII (NCGP) INC.
 its General Partner

			
	 	 	 By:
	 	 /s/ G. Bedell / Greg Gubitz

	 	 	 Name:
	 	 G. Bedell / Greg Gubitz

	 	 	 Title:
	 	 Secretary / Vice-President

			
	 	 	 Address:
	 	 100 International Blvd.

	 	 	 	 	 Toronto, Ontario

	 	 	 	 	 M9W 6J6

	 	 	 Fax:
	 	 

  

					
	 INTEGRA VENTURES III, L.P., SBIC,
 a Delaware limited partnership

		
	By:	 	 IV TECHNOLOGIES, LLC
 a Washington limited liability company

			
	 	 	 By:
	 	 /s/ Joseph K. Piper

	 	 	 Name:
	 	 Joseph K. Piper

	 	 	 Title:
	 	 Managing Director

			
	 	 	 Address:
	 	 300 E. Pine

	 	 	 	 	 Seattle, WA 98122

	 	 	 Fax:
	 	 (206) 832-1991

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

					
	BURRILL BIOTECHNOLOGY CAPITAL FUND, L.P.
		
	By:	 	 Burrill & Company (Biotechnology GP), LLC
 its General Manager

			
	 	 	 By:
	 	 /s/ G. Steven Burrill

	 	 	 Name:
	 	 G. Steven Burrill

	 	 	 Title:
	 	 Managing Member

			
	 	 	 Address:
	 	 One Embarcadero Center, Suite 2700

	 	 	 	 	 San Francisco, CA 94111

	 	 	 Fax:
	 	 (415) 591-5401

  

					
	BURRILL LIFE SCIENCES CAPITAL FUND, L.P.
		
	By:	 	 Burrill & Company (Life Sciences GP), LLC
 its General Manager

			
	 	 	 By:
	 	 /s/ G. Steven Burrill

	 	 	 Name:
	 	 G. Steven Burrill

	 	 	 Title:
	 	 Managing Member

			
	 	 	 Address:
	 	 One Embarcadero Center, Suite 2700

	 	 	 	 	 San Francisco, CA 94111

	 	 	 Fax:
	 	 (415) 591-5401

  

					
	BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.
		
	By:	 	 Burrill & Company (Indiana GP), LLC
 its General Manager

			
	 	 	 By:
	 	 /s/ G. Steven Burrill

	 	 	 Name:
	 	 G. Steven Burrill

	 	 	 Title:
	 	 Managing Member

			
	 	 	 Address:
	 	 One Embarcadero Center, Suite 2700

	 	 	 	 	 San Francisco, CA 94111

	 	 	 Fax:
	 	 (415) 591-5401

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	CASCADE INVESTMENT, L.L.C.
		
	By:	 	 /s/ Michael Larson

	 Name:
	 	 Michael Larson

	 Title:
	 	 Manager

		
	 Address:
	 	 2365 Carillon Point

	 	 	 Kirkland, WA 98033

	 Fax:
	 	 

  

			
	CADUCEUS PRIVATE INVESTMENTS, LP
		
	By:	 	 ORBIMED CAPITAL LLC,
 General Partner

		
	By:	 	 /s/ Eric A. Bittelman

	 Name:
	 	 Eric A. Bittelman

	 Title:
	 	 CFO, OrbiMed Capital, LLC

		
	 Address:
	 	 767 Third Avenue

	 	 	 New York, NY 10017

	 Fax:
	 	 

  

			
	ORBIMED ASSOCIATES LLC
		
	By:	 	 ORBIMED CAPITAL LLC,
 Managing Member

		
	By:	 	 /s/ Eric A. Bittelman

	 Name:
	 	 Eric A. Bittelman

	 Title:
	 	 CFO, OrbiMed Capital, LLC

		
	 Address:
	 	 767 Third Avenue

	 	 	 New York, NY 10017

	 Fax:
	 	 

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	 UBS JUNIPER CROSSOVER FUND, L.L.C.
 (FORMERLY CALLED PW JUNIPER CROSSOVER FUND, L.L.C.)

	 By:
	 	 ORBIMED ADVISORS LLC,
 Member

		
	By:	 	 /s/ Eric A. Bittelman

	 Name:
	 	 Eric A. Bittelman

	 Title:
	 	 CFO, OrbiMed Advisors, LLC

		
	 Address:
	 	 c/o PFPC Trust 8800

	 	 	 Tinicum Blvd., 3rd Floor

	 	 	 Philadelphia, PA 19153

	 	 	 Attn: Eric Kessler

	 Fax:
	 	 

  

			
	DIGITAL COAST VENTURES, L.L.C.
		
	By:	 	 /s/ James Montgomery

	 Name:
	 	 James Montgomery

	 Title:
	 	 Managing Director

		
	 Address:
	 	 100 Wilshire Boulevard, Suite 400

	 	 	 Santa Monica, CA 90401

	 Fax:
	 	 (310) 260-6095

  

			
	RBC LIFE SCIENCES LIMITED PARTNERSHIP II
		
	By:	 	 /s/Alan R Hibben / /s/ Robert Bechard

	 Name:
	 	 Alan R. Hibben / Robert Bechard

	 Title:
	 	 CFO / Managing Partner

		
	 Address:
	 	 4th
Floor North Tower

	 	 	 Royal Bank Plaza

	 	 	 Toronto, Ontario

	 	 	Canada M5J 2W7
	 	 	 Attn: Wesley Diong

	 Fax:
	 	 416-842-4060

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	ANTHEM/CIC VENTURES FUND, LP
		
	By:	 	 /s/ William Woodward

	 Name:
	 	 William Woodward

	 Title:
	 	 CEO

		
	 Address:
	 	 225 Arizona Avenue, #200
 Santa Monica, CA 90401

	 Fax:
	 	 
	
	ANTHEM INVEST, LTD.
		
	By:	 	 /s/ Boder Al-Rezainan

	 Name:
	 	 Boder Al-Rezainan

	 Title:
	 	 
		
	 Address:
	 	 
		
	 Fax:
	 	 
	
	WRW INVESTMENTS, LP
		
	By:	 	 /s/ William W. Woodward

	 Name:
	 	 William R. Woodward

	 Title:
	 	 Managing Member

		
	 Address:
	 	 
		
	 Fax:
	 	 
	
	GREG BONFIGLIO
		
	 	 	 /s/ Greg Bonfiglio

		
	 Address:
	 	 
		
	 Fax:
	 	 

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	TODD JERRY
		
	 	 	 /s/ Todd Jerry

	  
 Address:
	 	 
		
	 Fax:
	 	 
	
	BRIAN MESIC
		
	 	 	 /s/ Brian Mesic

	  
 Address:
	 	 
		
	 Fax:
	 	 
	
	CLAUDIA L. LLANOS
		
	 	 	 /s/ Claudia Llanos

	  
 Address:
	 	 
		
	 Fax:
	 	 
	
	GEORGE MONTGOMERY, JR., TTEE UNDER DECLARATION OF TRUST U/T/P
8/21/95
		
	 	 	 /s/ George Montgomery, Jr.

	  
 Address:
	 	  
 2838 Green Street

San Francisco, CA 94123

	 Fax:
	 	 
	
	CHARLES WALKER
		
	 	 	 /s/ Charles Walker

	  
 Address:
	 	  
 979 Baileyana
Road
 Hillsborough, CA 94010

	 Fax:
	 	 

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	WASHINGTON RESEARCH FOUNDATION
		
	By:	 	 /s/ Ronald S. Howell

	 Name:
	 	 Ronald S. Howell

	 Title:
	 	 President

		
	 Address:
	 	 2815 Eastlake Ave. E., Suite 300
 Seattle, WA 98102

	 Fax:
	 	 
	
	PACIFIC RIM AQUA LIFE SCIENCE NO. 1 INVESTMENT
PARTNERSHIP
	 By:   Pacific Rim Ventures Co., Ltd., its General Partner

		
	By:	 	 /s/ Masahiro Michishita, Ph.D.

	 Name:
	 	Masahiro Michishita, Ph.D.
	 Title:
	 	President and Managing General Partner
		
	 Address:
	 	 Green Plaza 2F 3-7-20 Komazawa
 Setagaya-ku, Tokyo
154-0012, Japan

	 Fax:
	 	011-81-3-5779-6753
	
	PACIFIC RIM AQUA LIFE SCIENCE NO. 2 INVESTMENT
PARTNERSHIP
	 By:   Pacific Rim Ventures Co., Ltd., its General Partner

		
	 By:
	 	 /s/ Masahiro Michishita, Ph.D.

	 Name:
	 	Masahiro Michishita, Ph.D.
	 Title:
	 	President and Managing General Partner
		
	 Address:
	 	Green Plaza 2F 3-7-20 Komazawa Setagaya-ku, Tokyo 154-0012, Japan
	 Fax:
	 	011-81-3-5779-6753

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	PACIFIC RIM AQUA LIFE SCIENCE NO. 3 INVESTMENT
PARTNERSHIP
	 By:   Pacific Rim Ventures Co., Ltd., its General Partner

		
	 By:
	 	 /s/ Masahiro Michishita, Ph.D.

	 Name:
	 	 Masahiro Michishita, Ph.D.

	 Title:
	 	 President and Managing General Partner

		
	 Address:
	 	Green Plaza 2F 3-7-20 Komazawa Setagaya-ku, Tokyo 154-0012, Japan
	 Fax:
	 	 011-81-3-5779-6753

	
	PACIFIC RIM AQUA LIFE SCIENCE NO. 4 INVESTMENT
PARTNERSHIP
	 By:   Pacific Rim Ventures Co., Ltd., its General Partner

		
	 By:
	 	 /s/ Masahiro Michishita, Ph.D.

	 Name:
	 	 Masahiro Michishita, Ph.D.

	 Title:
	 	 President and Managing General Partner

		
	 Address:
	 	Green Plaza 2F 3-7-20 Komazawa Setagaya-ku, Tokyo 154-0012, Japan
	 Fax:
	 	 011-81-3-5779-6753

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	ORRICK INVESTMENTS 2004 LLC
		
	By:	 	 /s/ Stephen M. Graham

	 Name:
	 	 Stephen M. Graham

	 Title:
	 	 Partner

	  
 Address:
	 	  
 719 Second Avenue, Suite
900
 Seattle, WA 98104

	 Fax:
	 	 (206) 839-4301

	
	STEPHEN M. GRAHAM
		
	 	 	 /s/ Stephen M. Graham

	  
 Address:
	 	  
 719 Second Avenue, Suite
900
 Seattle, WA 98104

	 Fax:
	 	 (206) 839-4301

	
	WESTRIVER CAPITAL LLC
		
	By:	 	 /s/ Eric Anderson

	 Name:
	 	 Erik Anderson

	 Title:
	 	 
	  
 Address:
	 	  
 2420 Carillon Point

Kirkland, WA 98033

	 Fax:
	 	 (425) 576-9868

	
	DONALD SEATON
		
	 	 	 /s/ Donald Seaton

	  
 Address:
	 	  
 2025 First Avenue, Suite
800
 Seattle, WA 98121

	 Fax:
	 	 (206) 728-5095

	
	YVES PIERRE GOBIN
		
	 	 	 /s/ Yves Pierre Gobin

	  
 Address:
	 	  
 6 Cayuga Trail
 Harrison, NY 10528

	 Fax:
	 	 (212) 746-6653

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	 ROBERTO FERRAROTTI

	
	         /s/ Roberto
Ferrarotti

		
	 Address:
	 	 966 Summer Holly Lane

	 	 	Encinitas, CA 92024
	 Fax:
	 	 (760) 943-7840

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	JIM JOHNSTON
	
	         /s/ Jim Johnston 

		
	 Address:
	 	 13801 NE 1st Place

	 	 	Bellevue, WA 98005
	 Fax:
	 	 (425) 828-7756

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	J. TAYLOR CRANDALL
	
	         /s/ J. Taylor
Crandall

		
	 Address:
	 	 145 Josselyn Lane

	 	 	Woodside, CA 94062
	 Fax:
	 	 (650) 234-0525

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	PHILLIP L. WILLIAMS, TRUSTEE,
	PHILLIP & JANE WILLIAMS
	LIVING TRUST UDT 8/20/85
	
	         /s/ Phillip L.
Williams

		
	 Address:
	 	 1156 Amalfi Drive

	 	 	Pacific Palisades, CA 90272
	 Fax:
	 	 (310) 459-6275

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	HANA VERNY
	
	         /s/ Hana Verny

		
	 Address:
	 	 2548 Greer Road

	 	 	Palo Alto, CA 94303
	 Fax:
	 	 (650) 324-1678

  
 *Signature Page to Information and Registration Rights Agreement* 
  

			
	MICHAEL J. MONTGOMERY
	
	         /s/ Michael J.
Montgomery

		
	 Address:
	 	 1135 Corsica Drive

	 	 	Pacific Palisades, CA 90272
	 Fax:
	 	 (___) ___-____

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	ELLEN R. GRANT
	
	         /s/ Ellen R. Grant

		
	 Address:
	 	 1130 20th Avenue East

	 	 	Seattle, WA 98112
	 Fax:
	 	 (206) 324-1208

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	RICHARD ROEDER
	
	         /s/ Richard Roeder

		
	 Address:
	 	 10877 Wilshire Blvd., Suite 2100

	 	 	Los Angeles, CA 90024
	 Fax:
	 	 (310) 824-2791

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	WALDRON AND COMPANY
		
	 By:
	 	 /s/ Dawn MacNab

	 Name:
	 	 Dawn MacNab

	 Title:
	 	 Principal

		
	 Address:
	 	 101 Stewart Street, Suite 1200

	 	 	 Seattle, WA 98101

	 Fax:
	 	 (206) 441-5213

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	RICHARD BOYD AND PATRICIA A. MONTGOMERY
	
	         /s/ Richard Boyd
Montgomery

	 Richard Boyd Montgomery

	
	         /s/ Patricia A.
Montgomery

	 Patricia A. Montgomery

		
	 Address:
	 	 46 N. Longspur Drive

	 	 	The Woodlands, TX 77380
	 Fax:
	 	 (281) 298-6270

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	ROBERT A. MONTGOMERY
	
	         /s/ Robert A.
Montgomery

		
	 Address:
	 	 645 14th Ave. West

	 	 	Kirkland, WA 98033
	 Fax:
	 	 (425) 827-3509

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	H. DAVID KENYON AND MEREDITH W. KENYON
	
	         /s/ H. David Kenyon

	 H. David Kenyon

	
	         /s/ Meredith W.
Kenyon

	 Meredith W. Kenyon

		
	 Address:
	 	 P.O. Box 557

	 	 	 Medina, WA 98039

	 Fax:
	 	 (425) 889-0151

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	MONTGOMERY REVOCABLE TRUST DTD 4/12/84
		
	 By:
	 	 /s/ Richard A. Montgomery

	 	 	 Richard A. Montgomery, Trustee

		
	 Address:
	 	 1398 Avenida de Cortez

	 	 	 Pacific Palisades, CA 90272

	 Fax:
	 	 310-459-2853

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	HEIDI KRISTINE MONTGOMERY
	
	         /s/ Heidi Kristine
Montgomery

		
	 Address:
	 	 348 Shore View Lane

	 	 	 Encinitas, CA 92024

	 Fax:
	 	 (760) 633-3442

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	WILBUR H. GANTZ III, TRUSTEE, WILBUR H. GANTZ III REVOCABLE TRUST
DATED 2/18/94 
	
	         /s/ Wilber H. Gantz
III

		
	 Address:
	 	 72 Indian Hill Road

	 	 	 Winnetka, IL 60093

	 Fax:
	 	 (847) 282-1004

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	KEVIN G. REILLY
	
	         /s/ Kevin G. Reilly

		
	 Address:
	 	 2890 Shadow Creek Drive

	 	 	 Apt. 305

	 	 	 Boulder, CO 80303

	 Fax:
	 	 (        )

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	THOMAS UNTERMAN, TRUSTEE, THOMAS AND JANET UNTERMAN LIVING
TRUST UTD 12/30/94
	
	         /s/ Thomas Unterman

		
	 Address:
	 	 1451 Amalfi Drive

	 	 	 Pacific Palisades, CA 90272

	 Fax:
	 	 (310) 998-8012

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	JOHN C. KEHOE
	
	         /s/ John C. Kehoe

		
	 Address:
	 	 8901 Fauntleroy Way SE

	 	 	 Seattle, WA 98136

	 Fax:
	 	 (425) 420-1077

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	THOMAS W. CARDY, TRUSTEE, THOMAS W. CARDY FAMILY
TRUST
	
	         /s/ Thomas W. Cardy

		
	 Address:
	 	 12808 Harborwood Drive

	 	 	 Largo, FL 33774

	 Fax:
	 	 (813) 287-8688

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	CLIFTON JARIUS STRATTON, III
	
	         /s/ Clifton Jarius Stratton
III

		
	 Address:
	 	 1002 37th Avenue East

	 	 	 Seattle, WA 98112

	 Fax:
	 	 (206) 622-0218

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	JAMES MONTGOMERY, TRUSTEE, JAMES W. MONTGOMERY FAMILY
TRUST
	
	         /s/ James Montgomery

		
	 Address:
	 	 11943 Kewsage Street

	 	 	 Los Angeles, CA 90049

	 Fax:
	 	 (310) 260-6095

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	IMPERIAL CAPITAL GROUP HOLDINGS LLC
		
	 By:
	 	 /s/ Jason Reese

	 	 	 Jason Reese

	 	 	 Its: Co-President

		
	 Address:
	 	 150 South Rodeo Drive, Suite 100

	 	 	 Beverly Hills, CA 90212

	 Fax:
	 	 (310) 777-3029

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	SCOTT MAYER, TRUSTEE, MAYER FAMILY REVOCABLE TRUST DATED
APRIL 24, 1997
	
	         /s/ Scott Mayer

		
	 Address:
	 	 701 S. Westgate Ave.

	 	 	 Los Angeles, CA 90049

	 Fax:
	 	 (310) 889-9182

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	JAN ERIC CLAESSON
	
	 /s/ Jan Eric Claesson

		
	 Address:
	 	 1829 Evergreen Pt. Road

	 	 	 Medina, WA 98039

	 Fax:
	 	 (425) 637-0552

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	PHILIP THOMAS PECSOK
	
	 /s/ Philip Thomas Pecsok

		
	 Address:
	 	 16653 Bienveneda Place

	 	 	 Pacific Palisades, CA 90272-2322

	 Fax:
	 	 (___) ___-_____

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	JOHN DAVID PAGE
	
	 /s/ John David Page

		
	 Address:
	 	 1911 65th Avenue West

	 	 	 Tacoma, WA 98466

	 Fax:
	 	 (253) 564-2762

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

			
	THOMAS J. MACCRORY
	
	 /s/ Thomas J. MacCrory

		
	 Address:
	 	 1380 Eaves Spring Road

	 	 	 Malvern, PA 19355

	 Fax:
	 	 (___) ___-_____

  
 *Signature
Page to Information and Registration Rights Agreement* 
  

 EXHIBIT A 
  
 INVESTORS 
  

	
	BX, L.P.
	Bear Stearns Health Innoventures, L.P.
	Bear Stearns Health Innoventures Offshore, L.P.
	BSHI Members, L.L.C.
	Bear Stearns Health Innoventures Employee Fund, L.P.
	J.P. Morgan Partners (SBIC), LLC
	J.P. Morgan Partners Global Investors (SBIC), LLC
	Cascade Investment, L.L.C.
	Burrill Biotechnology Capital Fund, L.P.
	Burrill Life Sciences Capital Fund, L.P.
	Burrill Indiana Life Sciences Capital Fund, L.P.
	SunAmerica Life Insurance Company
	H&Q Healthcare Investors
	H&Q Life Sciences Investors
	RBC Life Sciences Limited Partnership II
	Caduceus Private Investments, L.P.
	Orbimed Associates LLC
	UBS Juniper Crossover Fund, L.L.C (formerly PW Juniper Crossover Fund, L.L.C.)
	MDS Life Sciences Technology Fund II NC Limited Partnership
	MDS Life Sciences Technology Fund II Quebec Limited Partnership
	MLII Co-Investment Fund NC Limited Partnership
	Novo A/S
	MPM BioEquities Master Fund LP
	MPM BioEquities Fund GmbH & Co. KG
	Carnegie Fund II, Biotech Bridge Sub Fund
	T. Rowe Price Health Sciences Fund, Inc.
	Anthem/CIC Ventures Fund, LP
	Anthem Invest, LTD.
	Greg Bonfiglio
	Todd Jerry
	Claudia Llanos
	Brian Mesic
	WRW Investment, L.P.
	Pacific Rim Life Science No. 1 Investment Partnership
	Pacific Rim Life Science No. 2 Investment Partnership
	Pacific Rim AQUA Life Science No. 1 Investment Partnership
	Pacific Rim AQUA Life Science No. 2 Investment Partnership
	Pacific Rim AQUA Life Science No. 3 Investment Partnership
	Pacific Rim AQUA Life Science No. 4 Investment Partnership
	Cramer Holdings LLC
	Courtney M. Cramer
	Kirby L. Cramer, Jr.
	Kimberly C. Dyer

  

	
	Elizabeth E. Richard
	Corus Pharma Holdings
	Digital Coast Ventures
	Washington Research Foundation
	Integra Ventures III, L.P., SBIC
	WestRiver Capital LLC
	Radius Venture Partners I, L.P.
	George Montgomery, Jr., TTEE Under Declaration of Trust U/T/P 8/21/95
	Charles Walker
	Liberty Charitable Remainder Trust Dated 1/9/87
	MGN Opportunity Group LLC
	Orrick Investments 2004 LLC
	Donald Seaton
	William Baker
	Stephen M. Graham
	Jonathan P. Mow
	Ian Duncan
	Nancy McKinley
	T. Rowe Price Health Sciences, Inc.
	J. Taylor Crandall
	Roberto Ferrarotti
	Yves Pierre Gobin
	Hana Verny
	Jim Johnston
	Ellen Grant
	 Michael J. Montgomery
 Waldron and
Company

	Robert A. Montgomery
	H. David Kenyon and Meredith W. Kenyon
	Richard A Montgomery, Trustee, Montgomery Revocable Family Trust dtd 4/12/84
	Heidi Kristine Montgomery
	Clifton Jarius Stratton, III
	Wilbur H. Gantz III, Trustee, Wilbur H. Gatz III Revocable Trust Dated 2/18/94
	Kevin G. Reilly
	Thomas Unterman, Trustee, Thomas and Janet Unterman Living Trust UTD 12/30/94
	John C. Kehoe
	Richard Boyd and Patricia A. Montomery
	Thomas W. Cardy, Trustee, Thomas W. Cardy Family Trust
	James Montgomery, Trustee, James W. Montgomery Family Trust
	Imperial Capital Group Holdings LLC
	Scott Mayer, Trustee, Mayer Family Revocable Trust dated April 24, 1997
	Philip Thomas Pecsok
	Jan Eric Claesson
	John David Page
	Phillip L. Williams, Trustee, Phillip & Jane Williams Trust UTD 8-20-85
	Richard Roeder
	Thomas J. MacCrory

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]